Saturday, 27 March 2010

Clindamicina Fosfato




Clindamicina Fosfato may be available in the countries listed below.


Ingredient matches for Clindamicina Fosfato



Clindamycin

Clindamycin dihydrogen phosphate (a derivative of Clindamycin) is reported as an ingredient of Clindamicina Fosfato in the following countries:


  • Chile

  • Italy

International Drug Name Search

Mesren




Mesren may be available in the countries listed below.


Ingredient matches for Mesren



Mesalazine

Mesalazine is reported as an ingredient of Mesren in the following countries:


  • United Kingdom

International Drug Name Search

Friday, 26 March 2010

Otozone Solution


Pronunciation: klor-oh-ZYE-le-nole/HIGH-droe-CORE-tih-sone/pram-OX-een
Generic Name: Chloroxylenol/Hydrocortisone/Pramoxine
Brand Name: Examples include Cortane-B and Otozone


Otozone Solution is used for:

Treating certain infections of the outer ear canal that are complicated by inflammation. It is also used to control itching of the ear canal.


Otozone Solution is an antibacterial, steroid, and anesthetic combination. It works by killing bacteria, reducing inflammation, and temporarily relieving itching and pain.


Do NOT use Otozone Solution if:


  • you are allergic to any ingredient in Otozone Solution

  • you have chickenpox or vaccinia viral infection

  • your eardrum is perforated

Contact your doctor or health care provider right away if any of these apply to you.



Before using Otozone Solution:


Some medical conditions may interact with Otozone Solution. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

Some MEDICINES MAY INTERACT with Otozone Solution. Because little, if any, of Otozone Solution is absorbed into the blood, the risk of it interacting with another medicine is low.


Ask your health care provider if Otozone Solution may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Otozone Solution:


Use Otozone Solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Otozone Solution is only for the ear. Do not get it in your eyes, nose, or mouth. If you get Otozone Solution in the eyes, flush thoroughly with cool water.

  • Thoroughly clean and dry the outer ear before using Otozone Solution.

  • Lie down or tilt your head so that the affected ear faces up. For adults, gently pull the earlobe up and back to straighten the ear canal. For children, gently pull the earlobe down and back to straighten the ear canal. Drop the medicine into the ear canal. Keep the ear facing up for 5 minutes so the medicine can run to the bottom of the ear canal. A clean cotton plug may be gently inserted into the ear canal to prevent medicine from leaking out.

  • To prevent germs from getting into your medicine, do not touch the applicator to any surface, including the ear. Keep the container tightly closed.

  • Wash your hands immediately after using Otozone Solution.

  • If you miss a dose of Otozone Solution, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Otozone Solution.



Important safety information:


  • Do NOT use more than the recommended dose or use for longer than prescribed without checking with your doctor.

  • Do not use Otozone Solution for other conditions than the one for which it was prescribed.

  • Otozone Solution may cause harm if it is swallowed. If you may have taken it by mouth, contact your poison control center or emergency room right away.

  • Caution is advised when using Otozone Solution in CHILDREN; they may be more sensitive to its effects.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Otozone Solution while you are pregnant. It is not known if Otozone Solution is found in breast milk. If you are or will be breast-feeding while you use Otozone Solution, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Otozone Solution:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Dryness; itching.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); acne-like rash; burning, cracking, irritation, or peeling not present before you began using Otozone Solution; excessive hair growth; inflamed hair follicles; inflammation around the mouth; muscle weakness; thinning, softening, or discoloration of the skin; unusual weight gain, especially in the face.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Otozone side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Otozone Solution:

Store Otozone Solution at room temperature, between 59 and 86 degrees F (15 and 30 degrees C), in the original container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Otozone Solution out of the reach of children and away from pets.


General information:


  • If you have any questions about Otozone Solution, please talk with your doctor, pharmacist, or other health care provider.

  • Otozone Solution is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Otozone Solution. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Otozone resources


  • Otozone Side Effects (in more detail)
  • Otozone Use in Pregnancy & Breastfeeding
  • Otozone Support Group
  • 0 Reviews for Otozone - Add your own review/rating


Compare Otozone with other medications


  • Acute Otitis Externa
  • Ear Conditions
  • Otitis Externa

Friday, 19 March 2010

Adjusol




Adjusol may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Adjusol



Sulfadiazine

Sulfadiazine is reported as an ingredient of Adjusol in the following countries:


  • France

  • Portugal

Trimethoprim

Trimethoprim is reported as an ingredient of Adjusol in the following countries:


  • France

  • Portugal

International Drug Name Search

Wednesday, 17 March 2010

Trilafon




In the US, Trilafon (perphenazine systemic) is a member of the following drug classes: phenothiazine antiemetics, phenothiazine antipsychotics and is used to treat Bipolar Disorder, Nausea/Vomiting and Psychosis.

US matches:

  • Trilafon

Ingredient matches for Trilafon



Perphenazine

Perphenazine is reported as an ingredient of Trilafon in the following countries:


  • Canada

  • Denmark

  • Iceland

  • Indonesia

  • Italy

  • Japan

  • Luxembourg

  • Norway

  • Philippines

  • Poland

  • Sweden

  • Switzerland

Perphenazine enantate (a derivative of Perphenazine) is reported as an ingredient of Trilafon in the following countries:


  • Poland

International Drug Name Search

Tuesday, 16 March 2010

Buflomedil L.CH.




Buflomedil L.CH. may be available in the countries listed below.


Ingredient matches for Buflomedil L.CH.



Buflomedil

Buflomedil is reported as an ingredient of Buflomedil L.CH. in the following countries:


  • Chile

International Drug Name Search

Monday, 15 March 2010

Euraxsepti




Euraxsepti may be available in the countries listed below.


Ingredient matches for Euraxsepti



Chlorhexidine

Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Euraxsepti in the following countries:


  • France

International Drug Name Search

Sunday, 7 March 2010

Gleevec


Gleevec is a brand name of imatinib, approved by the FDA in the following formulation(s):


GLEEVEC (imatinib mesylate - tablet; oral)



  • Manufacturer: NOVARTIS

    Approval date: April 18, 2003

    Strength(s): EQ 100MG BASE, EQ 400MG BASE [RLD]

Has a generic version of Gleevec been approved?


No. There is currently no therapeutically equivalent version of Gleevec available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gleevec. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Pyrimidine derivatives and processes for the preparation thereof
    Patent 5,521,184
    Issued: May 28, 1996
    Inventor(s): Zimmermann; Jurg
    Assignee(s): Ciba-Geigy Corporation
    There are described N-phenyl-2-pyrimidine-amine derivatives of formula I ##STR1## wherein R.sub.1 is 4-pyrazinyl, 1-methyl-1H-pyrrolyl, amino- or amino-lower alkyl-substituted phenyl wherein the amino group in each case is free, alkylated or acylated, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen, R.sup.2, R.sup.3, R.sup.9, X, Y, n and R.sup.10 are defined in claim 1 These compounds can be used, for example, in the therapy of tumoral diseases.
    Patent expiration dates:

    • January 4, 2015
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • January 4, 2015
      ✓ 
      Patent use: A METHOD FOR TREATING A TUMOR DISEASE
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • January 4, 2015


    • July 4, 2015
      ✓ 
      Pediatric exclusivity




  • Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
    Patent 6,894,051
    Issued: May 17, 2005
    Inventor(s): Zimmermann; Jürg & Sutter; Bertrand & Bürger; Hans Michael
    Assignee(s): Novartis AG
    The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide of formula 1, which may be used for example for tumor therapy.
    Patent expiration dates:

    • May 23, 2019
      ✓ 
      Patent use: A METHOD FOR TREATING A TUMOR DISEASE
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • November 23, 2019
      ✓ 
      Pediatric exclusivity




  • Treatment of gastrointestinal stromal tumors
    Patent 6,958,335
    Issued: October 25, 2005
    Inventor(s): Buchdunger; Elisabeth & Capdeville; Renaud & Demetri; George Daniel & Dimitrijevic; Sasa & Druker; Brian Jay & Fletcher; Jonathan A. & Heinrich; Michael C. & Joensuu; Heikki & Silberman; Sandra Leta & Tuveson; David
    Assignee(s): Novartis AG
    Dana-Farber Cancer Institute, Inc.
    Oregon Health & Science University
    4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.
    Patent expiration dates:

    • December 19, 2021
      ✓ 
      Patent use: GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)


    • June 19, 2022
      ✓ 
      Pediatric exclusivity




  • Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
    Patent 7,544,799
    Issued: June 9, 2009
    Inventor(s): Zimmermann; Jürg & Sutter; Bertrand & Bürger; Hans M
    Assignee(s): Novartis AG
    The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula 1, which may be used for example for tumour therapy.
    Patent expiration dates:

    • January 16, 2019
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • July 16, 2019
      ✓ 
      Pediatric exclusivity



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 19, 2011 - ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST)

    • October 19, 2013 - ORPHAN DRUG EXCLUSIVITY

    • December 19, 2015 - ORPHAN DRUG EXCLUSIVITY

See also...

  • Gleevec Consumer Information (Drugs.com)
  • Gleevec Consumer Information (Wolters Kluwer)
  • Gleevec Consumer Information (Cerner Multum)
  • Gleevec Advanced Consumer Information (Micromedex)
  • Gleevec AHFS DI Monographs (ASHP)
  • Imatinib Consumer Information (Wolters Kluwer)
  • Imatinib Consumer Information (Cerner Multum)
  • Imatinib Advanced Consumer Information (Micromedex)
  • Imatinib Mesylate AHFS DI Monographs (ASHP)

Lactulosestroop




Lactulosestroop may be available in the countries listed below.


Ingredient matches for Lactulosestroop



Lactulose

Lactulose is reported as an ingredient of Lactulosestroop in the following countries:


  • Netherlands

International Drug Name Search

Saturday, 6 March 2010

Glyboral




Glyboral may be available in the countries listed below.


Ingredient matches for Glyboral



Glibenclamide

Glibenclamide is reported as an ingredient of Glyboral in the following countries:


  • Sri Lanka

International Drug Name Search

Friday, 5 March 2010

Cadral




Cadral may be available in the countries listed below.


Ingredient matches for Cadral



Cadralazine

Cadralazine is reported as an ingredient of Cadral in the following countries:


  • Japan

International Drug Name Search

Monday, 1 March 2010

Gripakin




Gripakin may be available in the countries listed below.


Ingredient matches for Gripakin



Chlorphenamine

Chlorphenamine maleate (a derivative of Chlorphenamine) is reported as an ingredient of Gripakin in the following countries:


  • Spain

Paracetamol

Paracetamol is reported as an ingredient of Gripakin in the following countries:


  • Spain

International Drug Name Search